COVID-19 vaccine | First Americans could be vaccinated on December 12: Report
The FDA advisory committee meets on December 10 to discuss Pfizer Inc’s request for an emergency use authorization for its COVID-19 vaccine candidate
November 23, 2020 / 07:14 AM IST
Representative Image (Image: Reuters)
The head of the US COVID-19 vaccine programme as said the first immunizations in America could happen as early as on December 12, just two days after the FDA advisory committee's meeting to discuss Pfizer Inc’s request for an emergency use authorization for its COVID-19 vaccine candidate.
"Our plan is to be able to ship vaccines to the immunization sites within 24 hours from the approval, so I expect maybe on day two after approval on the 11th or the 12th of December," CNN quoted Slaoui as saying.
Moderna, Pfizer and AstraZeneca: What is the latest on COVID-19 vaccine from the manufacturers?
Adding more, Dr Moncef Slaoui even stated that they are planning to ship the COVID-19 vaccines to states within 24 hours of the expected FDA approval. Recently, US pharmaceutical company Pfizer and its German partner BioNTech announced that the vaccine appears 95 percent effective at preventing mild to severe COVID-19 disease.
Meanwhile, Russian drugmaker Sputnik V claimed that its vaccine would be cheaper than those of Moderna and Pfizer. Moderna had earlier stated that its vaccine might be priced between $25 and $37 per dose.
"Translating pharma lingo: the announced price of Pfizer of $19.50 and Moderna of $25-$37 per dose actually means their price of $39 and $50-$74 per person. Two doses are required per person for the Pfizer, Sputnik V and Moderna vaccines. The price of Sputnik V will be much lower," Sputnik V wrote on Twitter on November 22.
While Pfizer with its partner BioNTech SE had stated that its COVID-19 vaccine candidate was 95 percent effective in the final analysis based on clinical trials data.
"The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world," Pfizer Chief Executive Albert Bourla said.